Literature DB >> 30937723

Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics.

Priyankar Pal1, Prabhas Prasun Giri2, Rajiv Sinha3.   

Abstract

OBJECTIVES: To assess the efficacy of cyclosporine (CsA) in patients of oral steroid unresponsive or steroid dependent systemic juvenile idiopathic arthritis (sJIA); to evaluate the optimum dosage and blood level of CsA to achieve and maintain remission and to observe for side-effects on prolonged usage.
METHODS: This prospective observational study was conducted on children with steroid dependent /refractory sJIA admitted at the Institute of Child Health, Kolkata from July 2009 through November 2014. A total of 82 sJIA was diagnosed; 15 were steroid dependent /refractory and were included as candidates for cyclosporine therapy.
RESULTS: CsA was used in 15 patients; 13 showed a favourable response with significant steroid sparing effect and minimal toxicity.
CONCLUSION: CsA was found to be effective in almost 75% of frequently relapsing steroid dependent sJIA to achieve and maintain remission. The average cost of therapy for a 20 kg patient on CsA was found to be 10,000 INR (132 EURO)/ patient over a 6 mo period; which would amount to 100,000 INR (1318 EURO)/patient with Tocilizumab for the same duration.

Entities:  

Keywords:  Cyclosporine; Systemic arthritis; Systemic juvenile idiopathic arthritis treatment

Mesh:

Substances:

Year:  2019        PMID: 30937723     DOI: 10.1007/s12098-019-02912-9

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  14 in total

1.  A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis.

Authors:  Salih Pay; Nuran Türkçapar; Mukaddes Kalyoncu; Ismail Simşek; Esin Beyan; Ihsan Ertenli; M Akif Oztürk; Nurşen Düzgün; Hakan Erdem; Zeynep Ozbalkan; Sedat Kiraz; Gülay Kinikli; Nesrin Besbas; Ayhan Dinç; Aşkin Ateş; Umit Olmez; Meral Calgüneri; Olcay Tiryaki Aydintuğ; Ayşin Bakkaloğlu; Mustafa Turan; Murat Turgay; Yaşar Karaaslan; Rezzan Topaloğlu; Murat Duman; Seza Ozen
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

2.  Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study.

Authors:  N Ruperto; A Ravelli; E Castell; V Gerloni; R Haefner; C Malattia; F Kanakoudi-Tsakalidou; S Nielsen; J Bohnsack; D Gibbas; R Rennebohm; O Voygioyka; Z Balogh; L Lepore; E Macejkova; N Wulffraat; S Oliveira; R Russo; A Buoncompagni; M O Hilário; M G Alpigiani; M Passo; D J Lovell; R Merino; A Martini; E H Giannini
Journal:  Clin Exp Rheumatol       Date:  2006 Sep-Oct       Impact factor: 4.473

Review 3.  Cyclosporine for rheumatoid arthritis.

Authors:  G Wells; D Haguenauer; B Shea; M E Suarez-Almazor; V A Welch; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.

Authors:  A Reiff; D J Rawlings; B Shaham; E Franke; L Richardson; I S Szer; B H Bernstein
Journal:  J Rheumatol       Date:  1997-12       Impact factor: 4.666

Review 5.  Benefit/risk of cyclosporine in rheumatoid arthritis.

Authors:  E Gremese; G F Ferraccioli
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

6.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

Authors:  Fabrizio De Benedetti; Hermine I Brunner; Nicolino Ruperto; Andrew Kenwright; Stephen Wright; Inmaculada Calvo; Ruben Cuttica; Angelo Ravelli; Rayfel Schneider; Patricia Woo; Carine Wouters; Ricardo Xavier; Lawrence Zemel; Eileen Baildam; Ruben Burgos-Vargas; Pavla Dolezalova; Stella M Garay; Rosa Merino; Rik Joos; Alexei Grom; Nico Wulffraat; Zbigniew Zuber; Francesco Zulian; Daniel Lovell; Alberto Martini
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

7.  Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis.

Authors:  A Ravelli; C Moretti; F Temporini; F Rossi; S Magni-Manzoni; A Pistorio; A Martini
Journal:  Clin Exp Rheumatol       Date:  2002 Jul-Aug       Impact factor: 4.473

8.  Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

Authors:  James W Verbsky; Andrew J White
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

9.  Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

Authors:  P Tugwell; T Pincus; D Yocum; M Stein; O Gluck; G Kraag; R McKendry; J Tesser; P Baker; G Wells
Journal:  N Engl J Med       Date:  1995-07-20       Impact factor: 91.245

10.  Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis.

Authors:  M Ostensen; H M Høyeraal; E Kåss
Journal:  J Rheumatol       Date:  1988-10       Impact factor: 4.666

View more
  5 in total

Review 1.  Cyclosporine for Systemic Onset Juvenile Idiopathic Arthritis: Current Stand and Future Directions.

Authors:  Narendra Kumar Bagri
Journal:  Indian J Pediatr       Date:  2019-06-01       Impact factor: 1.967

Review 2.  Research progress in drug therapy of juvenile idiopathic arthritis.

Authors:  Wen-Jia Zhao; Jiang-Hong Deng; Cai-Feng Li
Journal:  World J Pediatr       Date:  2022-04-01       Impact factor: 2.764

Review 3.  Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.

Authors:  William G Ambler; Kabita Nanda; Karen Brandt Onel; Susan Shenoi
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

4.  Cyclosporine-A-Based Immunosuppressive Therapy-Induced Neurotoxicity: A Case Report.

Authors:  Ali Teimouri; Sayyed Reza Ahmadi; Saeideh Anavri Ardakani; Mahdi Foroughian
Journal:  Open Access Emerg Med       Date:  2020-04-28

Review 5.  The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.

Authors:  Giuseppe Caruso; Anna Privitera; Barbara Moura Antunes; Giuseppe Lazzarino; Susan Marie Lunte; Giancarlo Aldini; Filippo Caraci
Journal:  Molecules       Date:  2022-07-12       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.